Research suggests that GLP-1 receptor agonists may have a complex effect on diabetic retinopathy, potentially increasing its incidence while also reducing its complications. However, the relationship between these drugs and vision problems is not entirely clear, with some studies indicating a possible increased risk of vision-altering conditions and others finding that the drugs may safeguard vision. The impact of GLP-1 receptor agonists on vision and diabetic retinopathy appears to be a subject of ongoing study and debate.